Abstract Number: VPB1375
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » VTE Prophylaxis
Background: Venous thromboembolism is extremely serious complication after endovenous ablation, occurring more frequently in patients with superficial and deep vein thrombosis in past medical history.
Aims: Evaluation of efficacy and safety of prolonged thromboprophylaxis after endovenous procedures in patients at high thrombotic risk.
Methods: 62 patients (28 males and 36 females with a mean age of 42.3±8.7 years) were included. 54 patients had a history of superficial vein thrombosis, which was conservatively treated (there were no clinical signs of phlebitis and complete or partial recanalization of the superficial veins was achieved). The average time from the onset of the phlebitis to the moment of ablation was 85 ± 12.2 days. 8 patients had history of deep vein thrombosis provoked by a major risk factor (complete recanalization of deep veins with reflux less than 1.5 seconds was detected in all patients).
In all patients, thromboprophylaxis with Apixaban 2.5 mg BID for 30 days after endovenous ablation was used. The detection of thromboembolism was based on serial ultrasound examination of the venous system at 1, 7, 30 and 90 days after ablation.
Results: None of the patients had life-threatening complications during the follow-up period (pulmonary embolism or major bleeding). In 1 patient (1,61%), distal deep vein thrombosis in the sural vein was detected 7 days after treatment, which was successfully treated with therapeutic doses of Apixaban for 3 months. In 2 patients (3,27%), EHIT 2 was noted, which was resolved spontaneously during 1-st month of observation. 2 patients (3,27%) had minor bleeding (1 nasal and 1 gynecological due to intrauterine polyp) during the observation period of 3 months.
Conclusion(s): Extended thromboprophylaxis with Apixaban 2.5 mg BID is a safe and effective approach in reducing the risk of thromboembolism in patients requiring endovenous ablation, but further studies are needed to test the hypothesis in a larger patient population.
To cite this abstract in AMA style:
Machuskyi S, Voloshyn O, Suzdalenko O, Gubka V, Pavlychenko V. Efficacy and safety of extended thromboprophylaxis with Apixaban after endovenous ablation for varicose veins in patients with a history of thrombophlebitis and venous thromboembolism [abstract]. https://abstracts.isth.org/abstract/efficacy-and-safety-of-extended-thromboprophylaxis-with-apixaban-after-endovenous-ablation-for-varicose-veins-in-patients-with-a-history-of-thrombophlebitis-and-venous-thromboembolism/. Accessed March 22, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/efficacy-and-safety-of-extended-thromboprophylaxis-with-apixaban-after-endovenous-ablation-for-varicose-veins-in-patients-with-a-history-of-thrombophlebitis-and-venous-thromboembolism/